Allergan Acquires Topokine Therapeutics

Apr 21, 2016

Allergan has announced that it has acquired Topokine Therapeutics, a Boston-based clinical-stage biotechnology company focused on developing topical medicines for fat reduction.

Under the terms of the agreement, Allergan will pay $85 million upfront, as well as success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as under-eye bags.

According to Allergan, XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients.

Read the Allergan press release